Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis：a Multicenter Retrospective Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pulmonary Fibrosis
- Sponsor
- China-Japan Friendship Hospital
- Enrollment
- 300
- Primary Endpoint
- The diagnostic rate of MDD2 based on TBLC
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this observational study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy（TBLC） in progressive pulmonary fibrosis.
Detailed Description
The goal of this observational study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy（TBLC） in progressive pulmonary fibrosis. The main question it aims to answer are: • The diagnostic rate of MDD1 or MDD2 based on TBLC. • The rate of hemorrhage, pneumothorax, acute ILD exacerbation and mortality. Participants' medical records will be collected by us.
Investigators
Gang Hou
Principal Investigator
China-Japan Friendship Hospital
Eligibility Criteria
Inclusion Criteria
- •Patients with PPF, ≥18 years of age, unclassified ILD, HRCT ≤3 months, forced vital capacity (FVC)≥50% predicted value, pulmonary carbon monoxide diffusion (DLCO)≥35% predicted value, echocardiography ≤12 months, estimated pulmonary systolic blood pressure ≤40 mmHg, Body mass index (BMI)≤35 kg/m2.
Exclusion Criteria
- •Patients with platelet counts below 50,000e+9/L or International Normalized ratio of prothrombin time (INR) above 1.5 are not eligible for TBLC
Outcomes
Primary Outcomes
The diagnostic rate of MDD2 based on TBLC
Time Frame: December，31，2024
the diagnostic rate of progressive pulmonary fibrosis after Transbronchial Cryobiopsy
Secondary Outcomes
- The diagnostic rate of MDD1(December，31，2024)